Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 457,100 shares, an increase of 61.1% from the November 30th total of 283,800 shares. Based on an average daily volume of 350,200 shares, the short-interest ratio is presently 1.3 days. Approximately 17.1% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $75.00 price objective on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

Aligos Therapeutics Stock Down 5.1 %

Aligos Therapeutics stock traded down $2.22 during mid-day trading on Friday, hitting $41.15. The company’s stock had a trading volume of 462,504 shares, compared to its average volume of 116,735. The stock has a market capitalization of $147.65 million, a P/E ratio of -3.09 and a beta of 2.71. Aligos Therapeutics has a twelve month low of $6.76 and a twelve month high of $44.39. The stock’s fifty day moving average price is $21.55 and its two-hundred day moving average price is $15.03.

Aligos Therapeutics (NASDAQ:ALGS) last announced its earnings results on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing the consensus estimate of ($2.15) by ($0.92). Aligos Therapeutics had a negative net margin of 1,283.19% and a negative return on equity of 114.34%. The company had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $1.00 million. During the same period in the prior year, the company earned ($10.25) earnings per share. Equities analysts expect that Aligos Therapeutics will post -10.36 earnings per share for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

An institutional investor recently raised its position in Aligos Therapeutics stock. Armistice Capital LLC increased its stake in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) by 5.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,256,410 shares of the company’s stock after acquiring an additional 363,000 shares during the quarter. Armistice Capital LLC owned about 9.29% of Aligos Therapeutics worth $2,540,000 at the end of the most recent reporting period. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).